BioCentury | Sep 10, 2020

Korro Bio’s $91.5M series A brings in new investors, launches hunt for CEO

Korro Bio’s $91.5 million series A round opens the door to new leadership for the Atlas-built RNA editing company, which has been led by Executive Chairman Nessan Bermingham since its launch in 2018. “With the series...
BioCentury | Aug 28, 2020

BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration

A collaboration between JLABS and BARDA gives the government agency access to start-ups that it needs to fast track new, innovative COVID-19 therapies and diagnostics it otherwise would struggle...
BioCentury | Jul 3, 2020
Translation in Brief

Tesla developing RNA therapeutic ‘microfactories’ for CureVac, plus CRISPR-directed RNA epigenetic modifications and Nucleix

Tesla ‘microfactories’ for CureVac Elon Musk tweeted on Wednesday that Tesla Grohmann Automation GmbH unit of Tesla Inc. (NASDAQ:TSLA) is building RNA “microfactories” for CureVac AG, which has an mRNA COVID-19 vaccine in the clinic....
BioCentury | May 23, 2020
Translation in Brief

A three-compound dengue treatment; plus reversing antibiotic resistance, AbCellera-Lilly, reducing cholesterol with CRISPR and COVID cash for Sherlock

Hindering dengue by combining host- and virus-targeted drugs In a Cell Chemical Biology article , Stanford University scientists combined two host-targeted compounds with a virus-targeted compound to yield potent dengue treatment. A DHODH inhibitor tool compound,...
BioCentury | May 7, 2020

CRISPR comes of age years ahead of schedule with first diagnostic authorization

FDA’s authorization of a CRISPR-based diagnostic for COVID-19 from Sherlock Biosciences is another step in the right direction for COVID-19 diagnostics, but it’s a much bigger win for the CRISPR technology. It represents the first...
BioCentury | May 2, 2020
Translation in Brief

ORIC’s CD73 inhibitor for cancer; plus Beam, CRISPR-Cas13 for respiratory infections, COVID-19 complex structure, and more

...serum AAT levels and elastase inhibitory capacity (see “ Beaming About Base Changes ” ). CRISPR-Cas13a...
...on bioRxiv, Georgia Institute of Technology and Emory University researchers showed that nebulized delivery of CRISPR-Cas13a...
...virus, directing CRISPR against an RNA polymerase subunit reduced death. In cells infected with SARS-CoV-2, Cas13a...
BioCentury | Apr 1, 2020
Product Development

A primer on the new coronavirus and COVID-19: BioCentury editors in conversation

The rapid pace at which COVID-19 has transformed society has rippled through the biopharma industry, affecting not only companies’ business strategies, but their product pipelines and priorities as many of them adapt on the fly...
BioCentury | Mar 28, 2020
Product Development

COVID-19 crisis spurs innovation in rapid diagnostic technologies

Companies across the world are mobilizing to answer the call for diagnostic innovation brought on by the COVID-19 crisis. The advances made during this time could change the course of this and future outbreaks, but...
BioCentury | Mar 28, 2020
Product Development

COVID-19 diagnostic tech tableau

In the ramp-up of testing for COVID-19, two well-established technologies have divided the forefront: RT-PCR and immunoassays. The former tests for active infection by detecting viral RNA, while the latter can be used to detect...
BioCentury | Mar 20, 2020
Tools & Techniques

COVID-19 crisis brings CRISPR-Cas13 research into the spotlight

It makes sense that CRISPR-Cas13 would enter the limelight during the COVID-19 crisis, given that the SARS-CoV-2 is an RNA virus, and this Cas enzyme targets RNA. With diagnostics one of the most critical components...
Items per page:
1 - 10 of 50